Abstract:Human risk assessment of the toxic potency of chemicals typically includes genotoxicity assays for predicting carcinogenicity. Gene mutation frequency and chromosomal aberration are two major genotoxicity endpoints in standardized in vitro and in vivo assays. The weight-of-evidence approach in risk assessment is more focused on in vivo assay results; however, animal welfare considerations are aimed at the reduction, replacement, and refinement (3R's) of animal experiments, including a reduction in the number of experimental animals. Proposals to reduce experimental animals in genotoxicity testing include the incorporation of genotoxicity endpoint(s) into other toxicological studies and the combination of two or more assays detecting different genotoxicity endpoints in the same animals. In this study, we used 1,2-dimethylhydrazine as a model chemical of colon carcinogen to assess gene mutation frequency and chromosomal aberration in vivo simultaneously. Specifically, a gene mutation frequency assay was combined with a multiple-organ micronucleus test (peripheral blood, bone marrow, liver, and colon) in F344 gpt delta transgenic rats. Both gpt mutant frequency and micronucleated cell frequency significantly increased in colon and liver but not in bone marrow. Interestingly, we found that the colon carcinogen induced both gene mutations and micronuclei in the targeted colon tissue. Thus, we demonstrated that the mechanism of a carcinogen could be derived from an animal experiment using a lower number of experimental animals as currently recommended. Moreover, a significant increase in mutant frequency in colon and liver was already observed on the first day after treatment completion, as well as on the third day, which is the guideline-recommended period. Thus, this endpoint is compatible with other genotoxicity assays. We confirmed that performing the micronucleus assay in combination with a gene mutation assay in F344 gpt delta transgenic rats is useful to evaluate different genotoxic endpoints simultaneously in the same animals, which reduces the number of experimental animals.

Assessment of Pig-a, Micronucleus and Comet Assay Endpoints in Tg.RasH2 Mice Carcinogenicity Study of Aristolochic Acid I.

Assessment of the Pig-a, micronucleus, and comet assay endpoints in rats treated by acute or repeated dosing protocols with procarbazine hydrochloride and ethyl carbamate.

PIG‐A Gene Mutation As a Genotoxicity Biomarker in Human Population Studies: an Investigation in Lead‐exposed Workers

Characterization of Pancreatic Lesions from MT-tgf Alpha, Ela-myc and MT-tgf Alpha/ela-Myc Single and Double Transgenic Mice.

PIG-A Gene Mutation As a Genotoxicity Biomaker in Polycyclic Aromatic Hydrocarbon-Exposed Barbecue Workers

Safety and Toxicology Study of Hu7691, a Novel AKT Inhibitor, Following Oral Administration in Rats

Benchmark Dose Analysis of Multiple Genotoxicity Endpoints in Gpt Delta Mice Exposed to Aristolochic Acid I

The in Vivo Pig-a Gene Mutation Assay is Applied to Study the Genotoxicity of Procarbazine Hydrochloride in Sprague-Dawley Rats

Assessment of the In Vitro Phosphatidylinositol Glycan Class A (PIG-A) Gene Mutation Assay Using Human TK6 and Mouse Hepa1c1c7 Cell Lines

[Genotoxicity Assessment of 2-Ethylhexyl Acrylate Using an in Vivo Pig-a Gene Mutation Assay Integrated System].

The PIG-A gene mutation assay in human biomonitoring and disease

A Population Study Using The Human Erythrocyte Pig-A Assay

Application of the in Vivo Pig-a Gene Mutation Assay to Test the Potential Genotoxicity of P-Phenylenediamine.

The Potential Application of Human PIG‐A Assay on Azathioprine‐treated Inflammatory Bowel Disease Patients

Premalignant Alteration Assessment in Liver-Like Tissue Derived from Embryonic Stem Cells by Aristolochic Acid I Exposure.

PIG-A gene mutation as a mutagenicity biomarker among coke oven workers

Tissue-specific Microrna Responses in Rats Treated with Mutagenic and Carcinogenic Doses of Aristolochic Acid.

Development of a Novel PIG-A Gene Mutation Assay Based on a GPI-anchored Fluorescent Protein Sensor

Hepatic Premalignant Alterations Triggered by Human Nephrotoxin Aristolochic Acid I in Canines

In vivo genotoxicity assessment of N‐(‐9 acridinyl)‐b‐alanine hydrochloride (S‐300) using a validated Pig‐a mutagenesis assay

Multiple-endpoint genotoxicity assay for colon carcinogen 1,2-dimethylhydrazine